 Douglas Seals
Concepts (734)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 185 | 2024 | 1612 | 22.520 |
Why?
| | Endothelium, Vascular | 82 | 2023 | 830 | 15.520 |
Why?
| | Vascular Stiffness | 41 | 2023 | 410 | 9.810 |
Why?
| | Oxidative Stress | 62 | 2023 | 1068 | 9.050 |
Why?
| | Exercise | 94 | 2023 | 1642 | 8.990 |
Why?
| | Vasodilation | 57 | 2022 | 418 | 7.160 |
Why?
| | Arteries | 31 | 2023 | 246 | 6.540 |
Why?
| | Brachial Artery | 38 | 2022 | 176 | 6.520 |
Why?
| | Blood Pressure | 98 | 2023 | 1531 | 6.380 |
Why?
| | Sympathetic Nervous System | 66 | 2023 | 171 | 6.210 |
Why?
| | Biomedical Research | 10 | 2023 | 582 | 4.300 |
Why?
| | Carotid Arteries | 25 | 2021 | 180 | 4.240 |
Why?
| | Writing | 7 | 2023 | 82 | 4.150 |
Why?
| | Aorta | 17 | 2023 | 388 | 3.920 |
Why?
| | Vascular Diseases | 15 | 2023 | 233 | 3.890 |
Why?
| | Antioxidants | 24 | 2023 | 529 | 3.590 |
Why?
| | Nitric Oxide | 33 | 2023 | 817 | 3.510 |
Why?
| | Cardiovascular Diseases | 28 | 2023 | 1726 | 3.500 |
Why?
| | Regional Blood Flow | 35 | 2020 | 421 | 3.480 |
Why?
| | Physical Endurance | 46 | 2016 | 232 | 3.220 |
Why?
| | Publishing | 5 | 2023 | 123 | 3.170 |
Why?
| | Sodium Nitrite | 8 | 2021 | 37 | 3.150 |
Why?
| | Heart Rate | 80 | 2023 | 710 | 3.080 |
Why?
| | Resistance Training | 5 | 2023 | 113 | 3.020 |
Why?
| | Aged | 163 | 2023 | 18971 | 2.990 |
Why?
| | Endothelial Cells | 20 | 2023 | 677 | 2.980 |
Why?
| | Mitochondria | 9 | 2023 | 744 | 2.720 |
Why?
| | Hypertension | 22 | 2023 | 1052 | 2.680 |
Why?
| | Middle Aged | 183 | 2023 | 26607 | 2.610 |
Why?
| | Caloric Restriction | 10 | 2021 | 89 | 2.560 |
Why?
| | Postmenopause | 24 | 2023 | 301 | 2.520 |
Why?
| | Dietary Supplements | 19 | 2023 | 459 | 2.490 |
Why?
| | Blood Vessels | 6 | 2020 | 179 | 2.470 |
Why?
| | Physical Exertion | 34 | 2014 | 209 | 2.340 |
Why?
| | Male | 243 | 2024 | 55400 | 2.300 |
Why?
| | Pulse Wave Analysis | 20 | 2023 | 207 | 2.220 |
Why?
| | Humans | 327 | 2023 | 114050 | 2.210 |
Why?
| | Inflammation | 23 | 2023 | 2464 | 2.210 |
Why?
| | Nitric Oxide Synthase Type III | 13 | 2020 | 181 | 2.170 |
Why?
| | Ascorbic Acid | 16 | 2023 | 110 | 2.160 |
Why?
| | Physical Fitness | 19 | 2013 | 180 | 2.110 |
Why?
| | Diet, Sodium-Restricted | 7 | 2020 | 34 | 2.110 |
Why?
| | Muscles | 32 | 2023 | 320 | 2.090 |
Why?
| | Physical Conditioning, Animal | 10 | 2021 | 194 | 2.080 |
Why?
| | Exercise Tolerance | 8 | 2023 | 212 | 2.040 |
Why?
| | NF-kappa B | 9 | 2015 | 636 | 1.990 |
Why?
| | Cardiovascular Physiological Phenomena | 13 | 2019 | 40 | 1.980 |
Why?
| | Oxygen Consumption | 43 | 2023 | 587 | 1.970 |
Why?
| | Methylamines | 5 | 2022 | 30 | 1.940 |
Why?
| | Peer Review | 4 | 2023 | 42 | 1.930 |
Why?
| | Superoxides | 16 | 2022 | 190 | 1.930 |
Why?
| | Baroreflex | 14 | 2016 | 54 | 1.820 |
Why?
| | Acetylcholine | 12 | 2023 | 166 | 1.790 |
Why?
| | Adult | 190 | 2023 | 30377 | 1.760 |
Why?
| | Mice | 50 | 2024 | 14845 | 1.720 |
Why?
| | Vasodilator Agents | 11 | 2017 | 302 | 1.700 |
Why?
| | Female | 168 | 2023 | 59328 | 1.650 |
Why?
| | Diet, Western | 3 | 2022 | 66 | 1.640 |
Why?
| | Animals | 79 | 2024 | 31567 | 1.640 |
Why?
| | Heart | 16 | 2018 | 613 | 1.590 |
Why?
| | Adipose Tissue | 17 | 2018 | 545 | 1.590 |
Why?
| | Norepinephrine | 28 | 2011 | 201 | 1.480 |
Why?
| | Physiology | 3 | 2023 | 9 | 1.460 |
Why?
| | Motor Activity | 8 | 2024 | 635 | 1.450 |
Why?
| | Respiratory Muscles | 5 | 2023 | 28 | 1.410 |
Why?
| | Salicylates | 5 | 2015 | 30 | 1.400 |
Why?
| | Forearm | 18 | 2023 | 112 | 1.390 |
Why?
| | NADPH Oxidases | 13 | 2020 | 105 | 1.390 |
Why?
| | Cellular Senescence | 6 | 2023 | 151 | 1.350 |
Why?
| | Healthy Aging | 3 | 2021 | 18 | 1.330 |
Why?
| | Research Personnel | 4 | 2023 | 147 | 1.320 |
Why?
| | Vascular Resistance | 19 | 2012 | 340 | 1.310 |
Why?
| | Mice, Inbred C57BL | 23 | 2024 | 4681 | 1.260 |
Why?
| | Estrogens | 8 | 2023 | 312 | 1.260 |
Why?
| | Reactive Oxygen Species | 13 | 2023 | 522 | 1.250 |
Why?
| | Double-Blind Method | 15 | 2023 | 1656 | 1.210 |
Why?
| | Tyrosine | 14 | 2020 | 210 | 1.190 |
Why?
| | Muscle, Skeletal | 21 | 2024 | 1468 | 1.180 |
Why?
| | Healthy Lifestyle | 2 | 2018 | 30 | 1.180 |
Why?
| | Aorta, Thoracic | 4 | 2014 | 257 | 1.140 |
Why?
| | Femoral Artery | 11 | 2013 | 165 | 1.120 |
Why?
| | Geriatrics | 4 | 2015 | 69 | 1.120 |
Why?
| | NAD | 5 | 2023 | 63 | 1.120 |
Why?
| | Autonomic Nervous System | 10 | 2008 | 66 | 1.110 |
Why?
| | Age Factors | 26 | 2021 | 2886 | 1.100 |
Why?
| | Smoking Water Pipes | 2 | 2023 | 5 | 1.080 |
Why?
| | Water Pipe Smoking | 2 | 2023 | 6 | 1.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2015 | 296 | 1.080 |
Why?
| | Estrogen Replacement Therapy | 12 | 2013 | 116 | 1.080 |
Why?
| | Metabolomics | 4 | 2021 | 511 | 1.040 |
Why?
| | Vasoconstriction | 6 | 2017 | 177 | 1.010 |
Why?
| | Longevity | 4 | 2015 | 136 | 1.010 |
Why?
| | Inflammation Mediators | 5 | 2018 | 475 | 1.000 |
Why?
| | Receptors, Adrenergic, beta | 6 | 2008 | 126 | 1.000 |
Why?
| | Gastrointestinal Microbiome | 3 | 2020 | 502 | 0.970 |
Why?
| | Cross-Over Studies | 10 | 2023 | 439 | 0.960 |
Why?
| | Cyclic N-Oxides | 8 | 2020 | 30 | 0.950 |
Why?
| | Elasticity | 11 | 2017 | 188 | 0.940 |
Why?
| | Curcumin | 2 | 2017 | 28 | 0.940 |
Why?
| | Drinking Water | 2 | 2022 | 64 | 0.930 |
Why?
| | Habits | 7 | 2017 | 36 | 0.920 |
Why?
| | Interleukin-1 | 5 | 2022 | 965 | 0.920 |
Why?
| | Body Temperature Regulation | 7 | 2007 | 72 | 0.890 |
Why?
| | Trehalose | 4 | 2017 | 30 | 0.880 |
Why?
| | Young Adult | 27 | 2023 | 10446 | 0.870 |
Why?
| | Transcriptome | 3 | 2023 | 723 | 0.870 |
Why?
| | Human Umbilical Vein Endothelial Cells | 3 | 2021 | 88 | 0.840 |
Why?
| | Obesity | 14 | 2023 | 2505 | 0.840 |
Why?
| | Fenofibrate | 2 | 2013 | 24 | 0.830 |
Why?
| | Vaping | 1 | 2023 | 45 | 0.830 |
Why?
| | Cardiorespiratory Fitness | 2 | 2021 | 35 | 0.830 |
Why?
| | Body Composition | 27 | 2012 | 590 | 0.830 |
Why?
| | Research Design | 4 | 2022 | 919 | 0.820 |
Why?
| | Elastin | 6 | 2023 | 78 | 0.820 |
Why?
| | Muscle Strength | 6 | 2023 | 271 | 0.810 |
Why?
| | Lyases | 1 | 2022 | 9 | 0.810 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2023 | 71 | 0.810 |
Why?
| | Nicotinamide Mononucleotide | 3 | 2023 | 9 | 0.800 |
Why?
| | Hypolipidemic Agents | 2 | 2013 | 86 | 0.800 |
Why?
| | Sodium, Dietary | 4 | 2013 | 36 | 0.800 |
Why?
| | Hemodynamics | 17 | 2023 | 1015 | 0.790 |
Why?
| | Stress, Physiological | 12 | 2017 | 379 | 0.790 |
Why?
| | Compliance | 12 | 2017 | 46 | 0.780 |
Why?
| | Speech | 1 | 2022 | 68 | 0.770 |
Why?
| | Rest | 12 | 2007 | 103 | 0.770 |
Why?
| | Aortitis | 2 | 2011 | 8 | 0.760 |
Why?
| | Spirostans | 1 | 2021 | 4 | 0.750 |
Why?
| | Breathing Exercises | 1 | 2021 | 18 | 0.750 |
Why?
| | Inhalation | 1 | 2021 | 26 | 0.750 |
Why?
| | Spin Labels | 8 | 2020 | 44 | 0.740 |
Why?
| | Biomarkers | 18 | 2023 | 3397 | 0.740 |
Why?
| | Superoxide Dismutase | 9 | 2016 | 305 | 0.740 |
Why?
| | Isometric Contraction | 14 | 1996 | 156 | 0.730 |
Why?
| | Running | 15 | 2017 | 207 | 0.730 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2021 | 1128 | 0.730 |
Why?
| | Autophagy | 3 | 2017 | 235 | 0.730 |
Why?
| | Comprehension | 1 | 2022 | 151 | 0.720 |
Why?
| | Reference Values | 26 | 2021 | 739 | 0.720 |
Why?
| | Cytokines | 10 | 2019 | 1824 | 0.720 |
Why?
| | Dementia | 1 | 2023 | 186 | 0.720 |
Why?
| | Doxorubicin | 2 | 2021 | 286 | 0.710 |
Why?
| | Fasting | 2 | 2020 | 242 | 0.700 |
Why?
| | Cardiac Output | 15 | 2004 | 143 | 0.700 |
Why?
| | Career Choice | 1 | 2022 | 178 | 0.700 |
Why?
| | Frailty | 1 | 2022 | 113 | 0.680 |
Why?
| | Nitroglycerin | 3 | 2020 | 19 | 0.680 |
Why?
| | Overweight | 3 | 2009 | 473 | 0.670 |
Why?
| | Adolescent | 45 | 2023 | 17802 | 0.670 |
Why?
| | Leg | 12 | 2007 | 224 | 0.670 |
Why?
| | Lipids | 6 | 2018 | 564 | 0.670 |
Why?
| | Life Style | 13 | 2017 | 428 | 0.670 |
Why?
| | Niacinamide | 3 | 2022 | 63 | 0.670 |
Why?
| | Mentoring | 1 | 2021 | 99 | 0.670 |
Why?
| | Sex Characteristics | 13 | 2011 | 636 | 0.660 |
Why?
| | Energy Metabolism | 8 | 2007 | 727 | 0.660 |
Why?
| | Physical Conditioning, Human | 1 | 2019 | 27 | 0.650 |
Why?
| | Spermidine | 2 | 2024 | 16 | 0.650 |
Why?
| | Nitrites | 3 | 2014 | 74 | 0.650 |
Why?
| | Cardiovascular System | 10 | 2020 | 126 | 0.630 |
Why?
| | Isoproterenol | 4 | 2007 | 105 | 0.630 |
Why?
| | Physical Education and Training | 14 | 2004 | 62 | 0.630 |
Why?
| | Adaptation, Physiological | 8 | 2019 | 484 | 0.620 |
Why?
| | Sirtuin 1 | 3 | 2016 | 29 | 0.620 |
Why?
| | Adrenergic beta-Agonists | 4 | 2007 | 125 | 0.610 |
Why?
| | Health Status | 3 | 2019 | 716 | 0.610 |
Why?
| | Amino Acids | 2 | 2019 | 445 | 0.610 |
Why?
| | Glycation End Products, Advanced | 3 | 2013 | 57 | 0.590 |
Why?
| | Lipoproteins, LDL | 10 | 2023 | 127 | 0.580 |
Why?
| | Body Constitution | 4 | 2005 | 47 | 0.580 |
Why?
| | Blood Volume | 8 | 1998 | 57 | 0.580 |
Why?
| | Sodium Chloride, Dietary | 3 | 2019 | 30 | 0.570 |
Why?
| | Vagus Nerve | 6 | 2005 | 79 | 0.570 |
Why?
| | Muscle, Smooth, Vascular | 6 | 2017 | 409 | 0.570 |
Why?
| | Extracellular Matrix | 1 | 2021 | 436 | 0.570 |
Why?
| | Tunica Intima | 7 | 2006 | 78 | 0.560 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2022 | 1880 | 0.560 |
Why?
| | Nitroprusside | 5 | 2011 | 64 | 0.560 |
Why?
| | Serine | 2 | 2015 | 125 | 0.540 |
Why?
| | Time Factors | 21 | 2021 | 6077 | 0.540 |
Why?
| | Models, Animal | 5 | 2021 | 340 | 0.540 |
Why?
| | Glucose | 3 | 2019 | 899 | 0.540 |
Why?
| | Muscle Contraction | 13 | 2003 | 389 | 0.540 |
Why?
| | Renal Insufficiency, Chronic | 5 | 2023 | 486 | 0.530 |
Why?
| | Transcription Factor RelA | 4 | 2011 | 80 | 0.530 |
Why?
| | Diet Therapy | 1 | 2016 | 36 | 0.530 |
Why?
| | Estradiol | 3 | 2021 | 450 | 0.530 |
Why?
| | Primary Prevention | 1 | 2018 | 172 | 0.520 |
Why?
| | Blood Glucose | 10 | 2017 | 1827 | 0.520 |
Why?
| | Cross-Sectional Studies | 21 | 2020 | 4402 | 0.520 |
Why?
| | Risk Factors | 19 | 2021 | 8614 | 0.510 |
Why?
| | Basal Metabolism | 3 | 2004 | 46 | 0.490 |
Why?
| | Epinephrine | 13 | 2007 | 163 | 0.490 |
Why?
| | Proteome | 1 | 2018 | 337 | 0.480 |
Why?
| | Collagen | 3 | 2021 | 414 | 0.480 |
Why?
| | Body Mass Index | 16 | 2015 | 1957 | 0.480 |
Why?
| | AMP-Activated Protein Kinases | 3 | 2017 | 170 | 0.470 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2014 | 15 | 0.470 |
Why?
| | Reflex | 6 | 2001 | 63 | 0.470 |
Why?
| | Geriatric Assessment | 2 | 2015 | 175 | 0.460 |
Why?
| | Endothelium | 1 | 2014 | 109 | 0.460 |
Why?
| | Nitrates | 4 | 2022 | 71 | 0.460 |
Why?
| | Ubiquinone | 1 | 2014 | 21 | 0.450 |
Why?
| | Atherosclerosis | 1 | 2018 | 342 | 0.450 |
Why?
| | Diet | 5 | 2016 | 1080 | 0.450 |
Why?
| | Premenopause | 8 | 2016 | 105 | 0.450 |
Why?
| | Niacin | 1 | 2013 | 18 | 0.440 |
Why?
| | Bufanolides | 1 | 2013 | 4 | 0.440 |
Why?
| | Vitamin B Complex | 1 | 2013 | 38 | 0.430 |
Why?
| | Hindlimb | 1 | 2014 | 130 | 0.430 |
Why?
| | Locomotion | 1 | 2014 | 81 | 0.430 |
Why?
| | Organophosphorus Compounds | 1 | 2014 | 72 | 0.430 |
Why?
| | Eating | 2 | 2007 | 344 | 0.430 |
Why?
| | Exercise Test | 12 | 2021 | 547 | 0.420 |
Why?
| | Hand Strength | 3 | 2023 | 97 | 0.420 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 200 | 0.420 |
Why?
| | Aortic Diseases | 1 | 2014 | 108 | 0.420 |
Why?
| | Cognition | 2 | 2020 | 990 | 0.410 |
Why?
| | Nitric Oxide Donors | 1 | 2012 | 15 | 0.410 |
Why?
| | Arm | 7 | 2008 | 104 | 0.410 |
Why?
| | Carotid Artery Diseases | 2 | 2010 | 57 | 0.400 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2015 | 1837 | 0.390 |
Why?
| | Obesity, Abdominal | 1 | 2012 | 37 | 0.390 |
Why?
| | Allopurinol | 2 | 2016 | 53 | 0.390 |
Why?
| | Neurodegenerative Diseases | 2 | 2023 | 92 | 0.380 |
Why?
| | Postural Balance | 1 | 2014 | 185 | 0.380 |
Why?
| | I-kappa B Proteins | 2 | 2009 | 80 | 0.380 |
Why?
| | Adrenal Glands | 3 | 2000 | 66 | 0.370 |
Why?
| | C-Reactive Protein | 3 | 2022 | 362 | 0.370 |
Why?
| | Arteritis | 1 | 2011 | 27 | 0.370 |
Why?
| | Athletic Performance | 2 | 2012 | 54 | 0.360 |
Why?
| | Cholesterol, LDL | 5 | 2008 | 307 | 0.360 |
Why?
| | Behavior, Animal | 1 | 2014 | 459 | 0.360 |
Why?
| | Uric Acid | 1 | 2012 | 148 | 0.360 |
Why?
| | Oxidants | 1 | 2011 | 112 | 0.360 |
Why?
| | Ganglionic Blockers | 6 | 2008 | 6 | 0.350 |
Why?
| | Athletes | 2 | 2022 | 328 | 0.350 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 1875 | 0.350 |
Why?
| | Hot Temperature | 5 | 1993 | 301 | 0.350 |
Why?
| | Metabolome | 3 | 2018 | 274 | 0.340 |
Why?
| | Analysis of Variance | 7 | 2011 | 1218 | 0.340 |
Why?
| | Forkhead Transcription Factors | 1 | 2011 | 170 | 0.340 |
Why?
| | Pressoreceptors | 5 | 1990 | 18 | 0.340 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1471 | 0.340 |
Why?
| | Ultrasonography | 9 | 2017 | 635 | 0.330 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2010 | 153 | 0.330 |
Why?
| | Peroxidase | 1 | 2010 | 161 | 0.330 |
Why?
| | Receptors, Adrenergic, beta-2 | 2 | 2007 | 39 | 0.320 |
Why?
| | Interleukins | 2 | 2022 | 236 | 0.320 |
Why?
| | Signal Transduction | 6 | 2014 | 4501 | 0.320 |
Why?
| | Biological Availability | 4 | 2021 | 119 | 0.320 |
Why?
| | Blood Circulation | 4 | 2021 | 36 | 0.320 |
Why?
| | Oxygen | 11 | 2022 | 851 | 0.310 |
Why?
| | Vitamin D | 2 | 2017 | 340 | 0.310 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 158 | 0.310 |
Why?
| | Administration, Oral | 5 | 2015 | 725 | 0.310 |
Why?
| | Systole | 5 | 2020 | 176 | 0.310 |
Why?
| | Leukocytes, Mononuclear | 1 | 2011 | 489 | 0.310 |
Why?
| | Upper Extremity | 1 | 2009 | 83 | 0.310 |
Why?
| | Ventricular Function, Left | 3 | 2003 | 477 | 0.310 |
Why?
| | Healthy Volunteers | 3 | 2018 | 191 | 0.300 |
Why?
| | Collagen Type I | 3 | 2014 | 108 | 0.300 |
Why?
| | NG-Nitroarginine Methyl Ester | 4 | 2013 | 38 | 0.300 |
Why?
| | Endothelin-1 | 2 | 2009 | 168 | 0.300 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 41 | 0.300 |
Why?
| | Sports | 5 | 2003 | 187 | 0.300 |
Why?
| | Peroneal Nerve | 5 | 2000 | 19 | 0.300 |
Why?
| | Abdomen | 5 | 2004 | 99 | 0.300 |
Why?
| | Phosphorylation | 6 | 2013 | 1558 | 0.290 |
Why?
| | Posture | 5 | 1997 | 152 | 0.290 |
Why?
| | Adiposity | 1 | 2012 | 458 | 0.290 |
Why?
| | Hypoxia | 6 | 1999 | 956 | 0.290 |
Why?
| | Infusions, Intravenous | 5 | 2014 | 370 | 0.290 |
Why?
| | Pilot Projects | 3 | 2020 | 1360 | 0.290 |
Why?
| | Treatment Outcome | 6 | 2021 | 9049 | 0.290 |
Why?
| | Human Experimentation | 1 | 2007 | 12 | 0.280 |
Why?
| | Enzyme Inhibitors | 4 | 2016 | 743 | 0.280 |
Why?
| | Acetophenones | 3 | 2019 | 14 | 0.280 |
Why?
| | Trimethaphan | 5 | 2005 | 5 | 0.280 |
Why?
| | Cells, Cultured | 4 | 2021 | 3861 | 0.270 |
Why?
| | Interleukin-6 | 3 | 2020 | 673 | 0.270 |
Why?
| | Regression Analysis | 9 | 2011 | 945 | 0.270 |
Why?
| | Gene Expression Regulation | 3 | 2017 | 2322 | 0.270 |
Why?
| | Energy Intake | 5 | 2020 | 427 | 0.270 |
Why?
| | Swimming | 5 | 2002 | 44 | 0.270 |
Why?
| | Phenylephrine | 5 | 2005 | 71 | 0.270 |
Why?
| | Tunica Media | 3 | 2001 | 35 | 0.270 |
Why?
| | Proteins | 3 | 2009 | 906 | 0.270 |
Why?
| | Nitric Oxide Synthase | 3 | 2014 | 209 | 0.260 |
Why?
| | Fatty Acids | 2 | 2019 | 380 | 0.260 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 496 | 0.260 |
Why?
| | Recovery of Function | 4 | 2017 | 573 | 0.260 |
Why?
| | Colorado | 5 | 2021 | 4090 | 0.250 |
Why?
| | Microcirculation | 2 | 2019 | 133 | 0.250 |
Why?
| | Carbon Dioxide | 3 | 2023 | 218 | 0.250 |
Why?
| | Cell Nucleus | 1 | 2008 | 552 | 0.250 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2007 | 270 | 0.250 |
Why?
| | Thermogenesis | 1 | 2005 | 37 | 0.250 |
Why?
| | MicroRNAs | 1 | 2011 | 600 | 0.250 |
Why?
| | Arginine | 1 | 2006 | 236 | 0.240 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 2 | 2011 | 35 | 0.240 |
Why?
| | American Heart Association | 2 | 2020 | 264 | 0.240 |
Why?
| | Electrocardiography | 8 | 2005 | 561 | 0.240 |
Why?
| | Weight Loss | 2 | 2008 | 642 | 0.230 |
Why?
| | Preventive Medicine | 2 | 2015 | 38 | 0.230 |
Why?
| | Skin | 4 | 2019 | 653 | 0.230 |
Why?
| | Apigenin | 1 | 2023 | 3 | 0.220 |
Why?
| | Flavonols | 1 | 2023 | 11 | 0.220 |
Why?
| | Respiratory Therapy | 1 | 2023 | 19 | 0.220 |
Why?
| | Lactates | 7 | 2007 | 78 | 0.220 |
Why?
| | Xanthine Oxidase | 3 | 2009 | 71 | 0.210 |
Why?
| | Blueberry Plants | 1 | 2023 | 4 | 0.210 |
Why?
| | Tissue Culture Techniques | 2 | 2014 | 66 | 0.210 |
Why?
| | Hand | 8 | 1994 | 135 | 0.210 |
Why?
| | Aged, 80 and over | 11 | 2023 | 6307 | 0.210 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2014 | 159 | 0.210 |
Why?
| | Myocardium | 5 | 2010 | 911 | 0.210 |
Why?
| | Cholesterol | 5 | 1997 | 368 | 0.210 |
Why?
| | Authorship | 1 | 2023 | 30 | 0.210 |
Why?
| | Blood Flow Velocity | 6 | 2019 | 388 | 0.210 |
Why?
| | Apoptosis | 1 | 2011 | 2349 | 0.200 |
Why?
| | Fibrinolysis | 2 | 2008 | 126 | 0.200 |
Why?
| | Anthropometry | 3 | 2011 | 183 | 0.200 |
Why?
| | Exercise Therapy | 6 | 2002 | 351 | 0.200 |
Why?
| | Terminology as Topic | 1 | 2023 | 186 | 0.200 |
Why?
| | Acetylene | 2 | 2003 | 3 | 0.200 |
Why?
| | Sugars | 1 | 2022 | 29 | 0.200 |
Why?
| | Supine Position | 6 | 1999 | 32 | 0.200 |
Why?
| | Adrenal Medulla | 1 | 2002 | 7 | 0.200 |
Why?
| | Coronary Disease | 6 | 1998 | 348 | 0.200 |
Why?
| | Respiration | 7 | 1998 | 180 | 0.200 |
Why?
| | Case-Control Studies | 3 | 2020 | 3003 | 0.200 |
Why?
| | Citrulline | 1 | 2022 | 39 | 0.190 |
Why?
| | Sirolimus | 3 | 2021 | 181 | 0.190 |
Why?
| | Body Weight | 10 | 2019 | 868 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2022 | 83 | 0.190 |
Why?
| | Weight Gain | 1 | 2004 | 453 | 0.190 |
Why?
| | Fatty Liver | 1 | 2023 | 209 | 0.190 |
Why?
| | Cyclooxygenase 2 | 2 | 2014 | 164 | 0.190 |
Why?
| | Nicotine | 1 | 2023 | 265 | 0.190 |
Why?
| | Progesterone | 1 | 2002 | 232 | 0.190 |
Why?
| | I-kappa B Kinase | 2 | 2011 | 50 | 0.180 |
Why?
| | Veins | 4 | 2009 | 55 | 0.180 |
Why?
| | Lung | 4 | 1999 | 3521 | 0.180 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2021 | 104 | 0.180 |
Why?
| | Free Radical Scavengers | 2 | 2013 | 78 | 0.180 |
Why?
| | Brain | 5 | 2023 | 2355 | 0.180 |
Why?
| | DNA Transposable Elements | 1 | 2021 | 97 | 0.180 |
Why?
| | Manuscripts as Topic | 1 | 2000 | 2 | 0.180 |
Why?
| | Knee | 1 | 2000 | 51 | 0.180 |
Why?
| | Insulin | 10 | 2022 | 2080 | 0.170 |
Why?
| | Myocardial Reperfusion Injury | 2 | 2011 | 95 | 0.170 |
Why?
| | Lipocalin-2 | 1 | 2020 | 61 | 0.170 |
Why?
| | Fibrinogen | 2 | 1998 | 143 | 0.170 |
Why?
| | Triglycerides | 4 | 2017 | 467 | 0.170 |
Why?
| | Rats | 11 | 2015 | 4913 | 0.170 |
Why?
| | Mentors | 1 | 2021 | 155 | 0.170 |
Why?
| | RNA, Untranslated | 1 | 2021 | 113 | 0.170 |
Why?
| | Menopause | 2 | 2006 | 271 | 0.170 |
Why?
| | Drug Monitoring | 1 | 2021 | 184 | 0.170 |
Why?
| | Pulmonary Circulation | 1 | 2001 | 407 | 0.170 |
Why?
| | Functional Food | 1 | 2019 | 2 | 0.160 |
Why?
| | Waist-Hip Ratio | 2 | 2012 | 30 | 0.160 |
Why?
| | Adipose Tissue, White | 1 | 2019 | 27 | 0.160 |
Why?
| | Cold Temperature | 6 | 1996 | 125 | 0.160 |
Why?
| | Adrenergic alpha-Agonists | 3 | 2005 | 29 | 0.160 |
Why?
| | Social Class | 1 | 2001 | 205 | 0.160 |
Why?
| | Adipokines | 1 | 2019 | 42 | 0.160 |
Why?
| | Transforming Growth Factor beta | 2 | 2012 | 445 | 0.160 |
Why?
| | Fluorescent Antibody Technique | 3 | 2009 | 396 | 0.160 |
Why?
| | Stroke Volume | 7 | 1998 | 513 | 0.160 |
Why?
| | Cohort Studies | 5 | 2013 | 4883 | 0.160 |
Why?
| | NF-KappaB Inhibitor alpha | 2 | 2009 | 52 | 0.160 |
Why?
| | Lower Body Negative Pressure | 4 | 1992 | 11 | 0.160 |
Why?
| | Guidelines as Topic | 1 | 2020 | 241 | 0.150 |
Why?
| | Linear Models | 2 | 2012 | 768 | 0.150 |
Why?
| | Metabolic Syndrome | 2 | 2019 | 320 | 0.150 |
Why?
| | Pyridinium Compounds | 1 | 2018 | 13 | 0.150 |
Why?
| | Leptin | 5 | 2019 | 210 | 0.150 |
Why?
| | Adipocytes | 1 | 2019 | 188 | 0.150 |
Why?
| | Methionine | 1 | 2018 | 144 | 0.150 |
Why?
| | Cardiology | 1 | 2020 | 260 | 0.150 |
Why?
| | Kidney | 5 | 2017 | 1182 | 0.140 |
Why?
| | Stress, Psychological | 3 | 1995 | 944 | 0.140 |
Why?
| | Unfolded Protein Response | 2 | 2017 | 44 | 0.140 |
Why?
| | Extremities | 1 | 1998 | 111 | 0.140 |
Why?
| | Cholecalciferol | 1 | 2017 | 47 | 0.140 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 147 | 0.140 |
Why?
| | Calcitriol | 1 | 2017 | 53 | 0.140 |
Why?
| | Neuromuscular Junction | 2 | 1995 | 53 | 0.140 |
Why?
| | Walking | 3 | 2011 | 422 | 0.140 |
Why?
| | Cognitive Dysfunction | 1 | 2021 | 282 | 0.140 |
Why?
| | Gene Regulatory Networks | 1 | 2018 | 229 | 0.140 |
Why?
| | Carotid Artery, Common | 1 | 2017 | 29 | 0.140 |
Why?
| | Congresses as Topic | 1 | 2018 | 193 | 0.130 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2017 | 92 | 0.130 |
Why?
| | Education, Graduate | 1 | 2016 | 29 | 0.130 |
Why?
| | Hyperuricemia | 1 | 2016 | 43 | 0.130 |
Why?
| | Blood Coagulation | 1 | 1998 | 200 | 0.130 |
Why?
| | Students, Health Occupations | 1 | 2016 | 23 | 0.130 |
Why?
| | Risk Assessment | 2 | 2018 | 2958 | 0.130 |
Why?
| | Age Distribution | 1 | 1997 | 341 | 0.130 |
Why?
| | Methemoglobin | 1 | 2015 | 19 | 0.130 |
Why?
| | Hemostasis | 2 | 1998 | 64 | 0.130 |
Why?
| | Program Development | 1 | 2018 | 339 | 0.130 |
Why?
| | Lipid Metabolism | 1 | 2018 | 441 | 0.120 |
Why?
| | Myocardial Contraction | 3 | 1988 | 318 | 0.120 |
Why?
| | Anaerobic Threshold | 3 | 2008 | 22 | 0.120 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 1995 | 48 | 0.120 |
Why?
| | Neurons | 2 | 1995 | 1277 | 0.120 |
Why?
| | Urinalysis | 1 | 2015 | 64 | 0.120 |
Why?
| | NADPH Oxidase 4 | 1 | 2014 | 8 | 0.120 |
Why?
| | Mitochondrial Proteins | 1 | 2016 | 213 | 0.120 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 2014 | 10 | 0.120 |
Why?
| | Shc Signaling Adaptor Proteins | 1 | 2014 | 10 | 0.120 |
Why?
| | Rotenone | 1 | 2014 | 4 | 0.120 |
Why?
| | Skinfold Thickness | 4 | 1999 | 49 | 0.120 |
Why?
| | Disease Models, Animal | 3 | 2015 | 3498 | 0.120 |
Why?
| | Rejuvenation | 1 | 2014 | 14 | 0.120 |
Why?
| | Nutritional Status | 1 | 2016 | 286 | 0.110 |
Why?
| | Glomerular Filtration Rate | 1 | 2017 | 605 | 0.110 |
Why?
| | Cell Cycle | 1 | 2016 | 541 | 0.110 |
Why?
| | Mobility Limitation | 1 | 2014 | 60 | 0.110 |
Why?
| | Prospective Studies | 6 | 2021 | 6195 | 0.110 |
Why?
| | Program Evaluation | 1 | 2018 | 820 | 0.110 |
Why?
| | Administration, Cutaneous | 1 | 2013 | 117 | 0.110 |
Why?
| | Epidemiology | 1 | 2013 | 14 | 0.110 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 1994 | 102 | 0.110 |
Why?
| | Multivariate Analysis | 2 | 2012 | 1422 | 0.110 |
Why?
| | Insulin Resistance | 2 | 2018 | 1072 | 0.110 |
Why?
| | Cardiotonic Agents | 1 | 2014 | 121 | 0.110 |
Why?
| | Absorptiometry, Photon | 2 | 2012 | 224 | 0.100 |
Why?
| | Respiratory Mechanics | 1 | 1993 | 56 | 0.100 |
Why?
| | Body Temperature | 5 | 1991 | 208 | 0.100 |
Why?
| | Statistics as Topic | 2 | 2011 | 291 | 0.100 |
Why?
| | Diabetic Angiopathies | 1 | 2015 | 246 | 0.100 |
Why?
| | Administration, Sublingual | 1 | 2012 | 13 | 0.100 |
Why?
| | Retrospective Studies | 4 | 2022 | 12521 | 0.100 |
Why?
| | Pyrogallol | 1 | 2012 | 3 | 0.100 |
Why?
| | Catecholamines | 5 | 1996 | 94 | 0.100 |
Why?
| | Mental Processes | 1 | 1992 | 34 | 0.100 |
Why?
| | Hypotension | 1 | 1993 | 115 | 0.100 |
Why?
| | Aminoimidazole Carboxamide | 1 | 2012 | 10 | 0.100 |
Why?
| | Ribonucleotides | 1 | 2012 | 24 | 0.100 |
Why?
| | United States | 3 | 2020 | 12137 | 0.100 |
Why?
| | Pulmonary Gas Exchange | 4 | 2007 | 117 | 0.100 |
Why?
| | Waist Circumference | 1 | 2012 | 122 | 0.100 |
Why?
| | Hysterectomy | 1 | 2012 | 105 | 0.100 |
Why?
| | Naphthols | 1 | 2011 | 7 | 0.090 |
Why?
| | Plethysmography | 3 | 2007 | 103 | 0.090 |
Why?
| | Receptors, Adrenergic, beta-3 | 1 | 2011 | 3 | 0.090 |
Why?
| | Nitroso Compounds | 1 | 2011 | 5 | 0.090 |
Why?
| | Chemokine CCL2 | 1 | 2011 | 104 | 0.090 |
Why?
| | Myography | 1 | 2011 | 4 | 0.090 |
Why?
| | Metabolism | 2 | 2001 | 35 | 0.090 |
Why?
| | Least-Squares Analysis | 1 | 2011 | 69 | 0.090 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 917 | 0.090 |
Why?
| | Forkhead Box Protein O3 | 1 | 2011 | 13 | 0.090 |
Why?
| | Glucose Tolerance Test | 3 | 2018 | 343 | 0.090 |
Why?
| | Communication | 1 | 2016 | 734 | 0.090 |
Why?
| | Diastole | 3 | 2003 | 137 | 0.090 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2010 | 16 | 0.090 |
Why?
| | Connective Tissue | 1 | 2010 | 36 | 0.090 |
Why?
| | Endorphins | 1 | 1990 | 7 | 0.090 |
Why?
| | Benzamides | 1 | 2011 | 168 | 0.090 |
Why?
| | Phosphoproteins | 1 | 2012 | 293 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2018 | 4392 | 0.090 |
Why?
| | Mice, Inbred Strains | 1 | 2011 | 398 | 0.090 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2010 | 56 | 0.090 |
Why?
| | Curriculum | 1 | 2016 | 813 | 0.090 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 53 | 0.090 |
Why?
| | Caspases | 1 | 2011 | 243 | 0.090 |
Why?
| | Liver | 2 | 2017 | 1633 | 0.090 |
Why?
| | Decompression | 1 | 1990 | 3 | 0.090 |
Why?
| | Fibronectins | 1 | 2010 | 108 | 0.090 |
Why?
| | Prognosis | 1 | 2018 | 3315 | 0.090 |
Why?
| | Prediabetic State | 1 | 2013 | 219 | 0.090 |
Why?
| | Lipoproteins, HDL | 3 | 1984 | 76 | 0.090 |
Why?
| | Sex Factors | 2 | 2011 | 1707 | 0.080 |
Why?
| | Diet Records | 1 | 2009 | 76 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 2 | 2010 | 2182 | 0.080 |
Why?
| | Acclimatization | 1 | 1990 | 147 | 0.080 |
Why?
| | Cyclooxygenase 1 | 1 | 2009 | 20 | 0.080 |
Why?
| | Subclavian Artery | 1 | 1989 | 29 | 0.080 |
Why?
| | Leukocyte Count | 1 | 2010 | 292 | 0.080 |
Why?
| | Receptor, Endothelin A | 1 | 2009 | 60 | 0.080 |
Why?
| | Homeostasis | 3 | 2021 | 570 | 0.080 |
Why?
| | Blood Pressure Determination | 1 | 2010 | 122 | 0.080 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 669 | 0.080 |
Why?
| | Probability | 1 | 2010 | 286 | 0.080 |
Why?
| | Carotid Sinus | 1 | 1988 | 2 | 0.080 |
Why?
| | Arrhythmia, Sinus | 1 | 1988 | 2 | 0.080 |
Why?
| | Sulfaphenazole | 1 | 2008 | 3 | 0.080 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 236 | 0.080 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2008 | 17 | 0.080 |
Why?
| | omega-N-Methylarginine | 1 | 2008 | 26 | 0.080 |
Why?
| | Leukocytes | 1 | 2010 | 272 | 0.080 |
Why?
| | Diet, High-Fat | 2 | 2021 | 225 | 0.080 |
Why?
| | Tetralogy of Fallot | 1 | 1989 | 81 | 0.080 |
Why?
| | Aortic Coarctation | 1 | 1989 | 70 | 0.080 |
Why?
| | Databases, Factual | 1 | 2013 | 1125 | 0.080 |
Why?
| | Estrogen Receptor alpha | 1 | 2009 | 121 | 0.080 |
Why?
| | Interferon-gamma | 1 | 2011 | 719 | 0.070 |
Why?
| | Telomere | 1 | 2010 | 202 | 0.070 |
Why?
| | Microscopy, Fluorescence | 1 | 2009 | 393 | 0.070 |
Why?
| | Vasoconstrictor Agents | 2 | 2007 | 113 | 0.070 |
Why?
| | Hyperemia | 1 | 1988 | 45 | 0.070 |
Why?
| | Hyperoxia | 2 | 1999 | 99 | 0.070 |
Why?
| | Catalase | 1 | 2007 | 118 | 0.070 |
Why?
| | Electrophysiology | 3 | 1993 | 201 | 0.070 |
Why?
| | Kinetics | 3 | 1997 | 1547 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2537 | 0.070 |
Why?
| | Amidohydrolases | 1 | 2006 | 28 | 0.070 |
Why?
| | Gene Expression | 1 | 2011 | 1417 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2008 | 318 | 0.070 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2007 | 106 | 0.060 |
Why?
| | Fibroblasts | 1 | 2010 | 834 | 0.060 |
Why?
| | Body Fat Distribution | 1 | 2005 | 46 | 0.060 |
Why?
| | Calorimetry, Indirect | 1 | 2005 | 69 | 0.060 |
Why?
| | Hematocrit | 2 | 1997 | 86 | 0.060 |
Why?
| | Heart Ventricles | 3 | 2003 | 723 | 0.060 |
Why?
| | Codon | 1 | 2005 | 85 | 0.060 |
Why?
| | Dihydroxyphenylalanine | 2 | 1995 | 7 | 0.060 |
Why?
| | Methoxyhydroxyphenylglycol | 2 | 1995 | 11 | 0.060 |
Why?
| | Vital Capacity | 2 | 2000 | 254 | 0.060 |
Why?
| | Erythrocyte Volume | 2 | 1994 | 4 | 0.060 |
Why?
| | Vasopressins | 1 | 2005 | 56 | 0.060 |
Why?
| | Plasma Volume | 2 | 1994 | 13 | 0.060 |
Why?
| | Calorimetry | 1 | 2004 | 60 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2011 | 2173 | 0.060 |
Why?
| | Thigh | 2 | 2003 | 53 | 0.060 |
Why?
| | Recombinant Proteins | 2 | 2018 | 1228 | 0.060 |
Why?
| | Macrophages | 1 | 2011 | 1259 | 0.060 |
Why?
| | Stroke | 2 | 2011 | 1019 | 0.060 |
Why?
| | Up-Regulation | 1 | 2007 | 802 | 0.060 |
Why?
| | Postprandial Period | 1 | 2004 | 87 | 0.060 |
Why?
| | Stem Cells | 1 | 2008 | 541 | 0.060 |
Why?
| | Osmolar Concentration | 3 | 2001 | 169 | 0.060 |
Why?
| | RNA, Messenger | 1 | 2011 | 2550 | 0.060 |
Why?
| | Mice, Transgenic | 2 | 2019 | 1947 | 0.060 |
Why?
| | T-Lymphocytes | 1 | 2011 | 1735 | 0.050 |
Why?
| | Phenotype | 1 | 2011 | 2784 | 0.050 |
Why?
| | Powders | 1 | 2023 | 38 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2272 | 0.050 |
Why?
| | Butanols | 1 | 2022 | 8 | 0.050 |
Why?
| | Hypercapnia | 1 | 2023 | 50 | 0.050 |
Why?
| | Electromyography | 3 | 1989 | 326 | 0.050 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2023 | 118 | 0.050 |
Why?
| | Biology | 1 | 2023 | 79 | 0.050 |
Why?
| | Phenols | 1 | 2023 | 82 | 0.050 |
Why?
| | Rats, Inbred Strains | 3 | 1991 | 360 | 0.050 |
Why?
| | Respiratory Function Tests | 2 | 1994 | 522 | 0.050 |
Why?
| | Ganglia, Autonomic | 1 | 2001 | 2 | 0.050 |
Why?
| | Ischemia | 5 | 1994 | 361 | 0.050 |
Why?
| | Genotype | 1 | 2007 | 1757 | 0.050 |
Why?
| | Men | 1 | 2001 | 17 | 0.050 |
Why?
| | Models, Biological | 2 | 2004 | 1611 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2015 | 2087 | 0.050 |
Why?
| | Lactic Acid | 4 | 1995 | 272 | 0.050 |
Why?
| | Clinical Trials as Topic | 2 | 2014 | 926 | 0.050 |
Why?
| | Tidal Volume | 2 | 1993 | 75 | 0.050 |
Why?
| | Acarbose | 1 | 2021 | 2 | 0.050 |
Why?
| | Drugs, Chinese Herbal | 1 | 2021 | 13 | 0.050 |
Why?
| | Neurons, Afferent | 2 | 1993 | 85 | 0.050 |
Why?
| | Blood Viscosity | 1 | 2001 | 14 | 0.050 |
Why?
| | Thoracic Arteries | 1 | 2000 | 4 | 0.050 |
Why?
| | Cerebrovascular Circulation | 1 | 2023 | 219 | 0.040 |
Why?
| | Mouth | 1 | 2021 | 69 | 0.040 |
Why?
| | Hypertrophy | 1 | 2001 | 110 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2020 | 35 | 0.040 |
Why?
| | Mexico | 1 | 2001 | 162 | 0.040 |
Why?
| | Organ Size | 2 | 2016 | 434 | 0.040 |
Why?
| | Thinness | 1 | 2000 | 87 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2005 | 1791 | 0.040 |
Why?
| | Stress, Mechanical | 2 | 2001 | 445 | 0.040 |
Why?
| | Heart Conduction System | 2 | 2000 | 80 | 0.040 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2003 | 371 | 0.040 |
Why?
| | Corticotropin-Releasing Hormone | 2 | 1991 | 67 | 0.040 |
Why?
| | Rats, Inbred F344 | 2 | 1990 | 241 | 0.040 |
Why?
| | Myocardial Infarction | 2 | 2005 | 932 | 0.040 |
Why?
| | NADP | 1 | 2019 | 42 | 0.040 |
Why?
| | Head-Down Tilt | 1 | 1999 | 5 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2022 | 428 | 0.040 |
Why?
| | Prevalence | 2 | 2005 | 2247 | 0.040 |
Why?
| | Receptors, Interleukin-1 Type I | 1 | 2018 | 22 | 0.040 |
Why?
| | Hyperinsulinism | 1 | 2019 | 103 | 0.040 |
Why?
| | Acute Disease | 1 | 2000 | 908 | 0.040 |
Why?
| | Biological Transport | 1 | 2019 | 374 | 0.040 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2017 | 16 | 0.040 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 1998 | 75 | 0.040 |
Why?
| | Automation | 1 | 1997 | 74 | 0.040 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 1998 | 79 | 0.040 |
Why?
| | Mathematics | 2 | 1996 | 107 | 0.040 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 1998 | 131 | 0.040 |
Why?
| | Echocardiography | 2 | 2005 | 569 | 0.040 |
Why?
| | Rotarod Performance Test | 1 | 2017 | 16 | 0.040 |
Why?
| | Cell Respiration | 1 | 2017 | 71 | 0.030 |
Why?
| | Splanchnic Circulation | 2 | 1999 | 10 | 0.030 |
Why?
| | Adenylate Kinase | 1 | 2016 | 26 | 0.030 |
Why?
| | Weight Lifting | 3 | 1988 | 29 | 0.030 |
Why?
| | Muscle Development | 1 | 1997 | 99 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2384 | 0.030 |
Why?
| | Myoblasts | 1 | 2017 | 76 | 0.030 |
Why?
| | Body Height | 1 | 1997 | 180 | 0.030 |
Why?
| | Oxidative Phosphorylation | 1 | 2017 | 154 | 0.030 |
Why?
| | Tissue Plasminogen Activator | 1 | 1998 | 204 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2017 | 228 | 0.030 |
Why?
| | Resilience, Psychological | 1 | 2017 | 95 | 0.030 |
Why?
| | Pain | 2 | 1992 | 701 | 0.030 |
Why?
| | Cholesterol, HDL | 3 | 1984 | 184 | 0.030 |
Why?
| | Menstruation | 1 | 1995 | 35 | 0.030 |
Why?
| | Indicator Dilution Techniques | 1 | 1995 | 9 | 0.030 |
Why?
| | Haplorhini | 1 | 2015 | 57 | 0.030 |
Why?
| | Receptors, Leptin | 1 | 2015 | 24 | 0.030 |
Why?
| | Protein Kinases | 1 | 2017 | 304 | 0.030 |
Why?
| | Autonomic Fibers, Postganglionic | 1 | 1994 | 1 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2003 | 2764 | 0.030 |
Why?
| | Spectrophotometry | 1 | 1994 | 47 | 0.030 |
Why?
| | Median Nerve | 1 | 1994 | 20 | 0.030 |
Why?
| | Neurotransmitter Agents | 1 | 1995 | 75 | 0.030 |
Why?
| | Educational Measurement | 1 | 2016 | 235 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2015 | 271 | 0.030 |
Why?
| | Homozygote | 1 | 2015 | 187 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2014 | 55 | 0.030 |
Why?
| | Heterozygote | 1 | 2015 | 250 | 0.030 |
Why?
| | Gated Blood-Pool Imaging | 1 | 1994 | 5 | 0.030 |
Why?
| | Point Mutation | 1 | 2015 | 216 | 0.030 |
Why?
| | Health | 1 | 2014 | 74 | 0.030 |
Why?
| | Propranolol | 3 | 2001 | 46 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 445 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2016 | 359 | 0.030 |
Why?
| | Activating Transcription Factor 6 | 1 | 2013 | 16 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2017 | 813 | 0.030 |
Why?
| | Microbiota | 1 | 2021 | 648 | 0.030 |
Why?
| | eIF-2 Kinase | 1 | 2013 | 24 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2015 | 271 | 0.030 |
Why?
| | Reflex, Stretch | 1 | 1993 | 9 | 0.030 |
Why?
| | Heart-Lung Transplantation | 1 | 1993 | 9 | 0.030 |
Why?
| | Denervation | 1 | 1993 | 18 | 0.030 |
Why?
| | Endoribonucleases | 1 | 2013 | 62 | 0.030 |
Why?
| | Venous Pressure | 1 | 1992 | 8 | 0.030 |
Why?
| | Synaptic Transmission | 1 | 1995 | 227 | 0.030 |
Why?
| | Chemoreceptor Cells | 1 | 1993 | 55 | 0.030 |
Why?
| | Age of Onset | 1 | 2014 | 444 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 549 | 0.030 |
Why?
| | Fingers | 1 | 2013 | 81 | 0.030 |
Why?
| | Skin Temperature | 1 | 1992 | 16 | 0.030 |
Why?
| | Tissue Distribution | 1 | 1993 | 285 | 0.030 |
Why?
| | Ovariectomy | 1 | 2012 | 116 | 0.020 |
Why?
| | Cell Line | 1 | 2017 | 2629 | 0.020 |
Why?
| | Renal Circulation | 1 | 1991 | 53 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 1992 | 160 | 0.020 |
Why?
| | Endoplasmic Reticulum | 1 | 2013 | 234 | 0.020 |
Why?
| | Cardiography, Impedance | 1 | 1991 | 6 | 0.020 |
Why?
| | Metformin | 1 | 2014 | 274 | 0.020 |
Why?
| | Precision Medicine | 1 | 2014 | 335 | 0.020 |
Why?
| | Inspiratory Capacity | 1 | 1990 | 2 | 0.020 |
Why?
| | Acupuncture Therapy | 1 | 1990 | 16 | 0.020 |
Why?
| | Arousal | 1 | 1991 | 152 | 0.020 |
Why?
| | Blood Pressure Monitors | 1 | 1989 | 2 | 0.020 |
Why?
| | Anorexia Nervosa | 1 | 1990 | 63 | 0.020 |
Why?
| | Lipoproteins | 2 | 1988 | 159 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2011 | 771 | 0.020 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2001 | 286 | 0.020 |
Why?
| | Fever | 1 | 1990 | 280 | 0.020 |
Why?
| | Menstrual Cycle | 1 | 2009 | 108 | 0.020 |
Why?
| | Total Lung Capacity | 1 | 1988 | 30 | 0.020 |
Why?
| | Child | 3 | 1997 | 18404 | 0.020 |
Why?
| | Neural Inhibition | 1 | 1989 | 139 | 0.020 |
Why?
| | Postoperative Period | 1 | 1989 | 288 | 0.020 |
Why?
| | Saponins | 1 | 1988 | 6 | 0.020 |
Why?
| | Digoxin | 1 | 1988 | 26 | 0.020 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 2007 | 39 | 0.020 |
Why?
| | Hormones | 1 | 1988 | 132 | 0.020 |
Why?
| | Pain Management | 1 | 1990 | 285 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2013 | 1016 | 0.020 |
Why?
| | Adrenergic Fibers | 1 | 1987 | 4 | 0.020 |
Why?
| | Depressive Disorder | 1 | 1990 | 330 | 0.020 |
Why?
| | Environmental Exposure | 1 | 1991 | 372 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2009 | 1003 | 0.020 |
Why?
| | Kidney Diseases | 1 | 2011 | 349 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 198 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 1988 | 471 | 0.020 |
Why?
| | Fatigue | 1 | 1988 | 294 | 0.020 |
Why?
| | Down-Regulation | 1 | 2009 | 594 | 0.020 |
Why?
| | Heart Block | 1 | 1986 | 39 | 0.020 |
Why?
| | Syncope | 1 | 1986 | 38 | 0.020 |
Why?
| | Blood Proteins | 1 | 1988 | 222 | 0.020 |
Why?
| | Peptide Fragments | 1 | 1990 | 665 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1204 | 0.020 |
Why?
| | Feedback | 1 | 2005 | 144 | 0.020 |
Why?
| | DNA Methylation | 1 | 2009 | 493 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2011 | 2563 | 0.010 |
Why?
| | Dogs | 1 | 2005 | 331 | 0.010 |
Why?
| | Hemostatics | 1 | 2005 | 44 | 0.010 |
Why?
| | Anabolic Agents | 1 | 1984 | 11 | 0.010 |
Why?
| | Affect | 1 | 2007 | 246 | 0.010 |
Why?
| | Drug Tolerance | 1 | 1984 | 77 | 0.010 |
Why?
| | Arrhythmias, Cardiac | 1 | 1986 | 282 | 0.010 |
Why?
| | C-Peptide | 1 | 1984 | 138 | 0.010 |
Why?
| | Methods | 1 | 1983 | 57 | 0.010 |
Why?
| | Work Capacity Evaluation | 1 | 2002 | 11 | 0.010 |
Why?
| | Androgens | 1 | 1984 | 167 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1983 | 167 | 0.010 |
Why?
| | Motivation | 1 | 2007 | 488 | 0.010 |
Why?
| | Heart Arrest | 1 | 1986 | 293 | 0.010 |
Why?
| | Wrestling | 1 | 1982 | 2 | 0.010 |
Why?
| | Gymnastics | 1 | 1982 | 21 | 0.010 |
Why?
| | Sodium Chloride | 1 | 2001 | 133 | 0.010 |
Why?
| | Efferent Pathways | 2 | 1992 | 15 | 0.010 |
Why?
| | Femur | 1 | 2001 | 191 | 0.010 |
Why?
| | Renal Veins | 1 | 1999 | 10 | 0.010 |
Why?
| | Jugular Veins | 1 | 1999 | 38 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2000 | 179 | 0.010 |
Why?
| | Oscillometry | 1 | 1998 | 33 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 2001 | 493 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1998 | 102 | 0.010 |
Why?
| | Self Concept | 1 | 1996 | 211 | 0.010 |
Why?
| | Pain Measurement | 1 | 1992 | 441 | 0.010 |
Why?
| | Injections, Intraventricular | 1 | 1990 | 71 | 0.010 |
Why?
| | Pancreatic Hormones | 1 | 1988 | 3 | 0.000 |
Why?
| | Thyroid Hormones | 1 | 1988 | 53 | 0.000 |
Why?
| | Cardenolides | 1 | 1988 | 1 | 0.000 |
Why?
| | Glycerol | 1 | 1988 | 84 | 0.000 |
Why?
| | Growth Hormone | 1 | 1988 | 103 | 0.000 |
Why?
| | Fatty Acids, Nonesterified | 1 | 1988 | 150 | 0.000 |
Why?
| | Insulin-Like Growth Factor I | 1 | 1988 | 286 | 0.000 |
Why?
| | Differential Threshold | 1 | 1985 | 5 | 0.000 |
Why?
| | Maximal Voluntary Ventilation | 1 | 1985 | 8 | 0.000 |
Why?
| | Risk | 1 | 1987 | 810 | 0.000 |
Why?
| | Action Potentials | 1 | 1987 | 406 | 0.000 |
Why?
| | Bicycling | 1 | 1985 | 86 | 0.000 |
Why?
| | Ammonia | 1 | 1984 | 56 | 0.000 |
Why?
| | Testosterone | 1 | 1984 | 341 | 0.000 |
Why?
| | Substance-Related Disorders | 1 | 1984 | 942 | 0.000 |
Why?
|
|
Seals's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|